Resistance to Integrase Inhibitors

Integrase (IN) is a clinically validated target for the treatment of human immunodeficiency virus infections and raltegravir exhibits remarkable clinical activity. The next most advanced IN inhibitor is elvitegravir. However, mutant viruses lead to treatment failure and mutations within the IN codin...

Descripción completa

Detalles Bibliográficos
Autores principales: Métifiot, Mathieu, Marchand, Christophe, Maddali, Kasthuraiah, Pommier, Yves
Formato: Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920056/
https://www.ncbi.nlm.nih.gov/pubmed/20706558
http://dx.doi.org/10.3390/v2071347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920056/
https://www.ncbi.nlm.nih.gov/pubmed/20706558
http://dx.doi.org/10.3390/v2071347

Ejemplares similares